Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects
Summary
Parkinson’s disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of Parkinson’s disease (PD) are common. In particular, PD-associated dementia and PD-associated psychosis are highly prevalent and associated with a large disease burden.
There is a pressing unmet need within Parkinson’s disease (PD), as well as PD-associated dementia and PD-associated psychosis, for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relief, there are no commercially available agents capable of preventing or slowing the course of Parkinson’s disease (PD) or its behavioral complications. This reflects the complexity of these diseases and the incomplete understanding of disease pathogenesis.
There is considerable evidence that R&D within Parkinson’s disease (PD) is thriving, despite the high risk of failure associated with product development. The Parkinson’s disease (PD) pipeline is large and diverse, comprising 456 active products. The pipeline is also highly innovative, as 51.1% of pipeline products with a disclosed molecular target are first-in-class. This is notably higher than the proportion across the industry as a whole, which is approximately 40%.
Analysis of the PD pipeline demonstrates a shift in focus from symptomatic alleviation to potential disease-modifying strategies. The pipeline comprises a range of novel mechanisms not observed in the market, including therapies that promote neurogenesis or immunomodulatory effects, and therapies that reduce neurotoxicity by preventing aggregation of misfolded proteins.
Far fewer products are in development for behavioral complications of PD. There are 16 products in development for PD-associated dementia, of which 12 have a disclosed molecular target. However, encouragingly, the majority of these products-nine in total-are first-in-class. Only six pipeline products have been identified within the PD-associated psychosis pipeline, five of which have a disclosed molecular target. However, none of these products are first-in-class.
Less than a third of products in active development for Parkinson’s disease (PD), PD-associated dementia, or PD-associated psychosis have prior involvement in licensing or co-development deals. Notably, products associated with the largest deal values are predominately first-in-class, a trend that is attributable to the stronger commercial potential of first-in-class products. Additionally, some of the largest deal values relate to gene therapies, examples of which include VYAADC-01, ‘Gene Therapy to Inhibit SNCA for Neurology,’ AXO-Lenti-PD, and OXB-101. This provides further evidence that pharma companies are diversifying their approaches by investing more substantially in more innovative molecule types.
However, of the 467 products in active development within these indications, 326 (69.8%) have no prior involvement in licensing or co-development deals and therefore represent potential investment opportunities. This includes 96 first-in-class products that act on a diverse range of targets.
The report “Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects” focuses on Parkinson’s disease (PD), as well as PD-associated dementia and PD-associated psychosis, two behavioral complications of PD associated with large quality-of-life impairments and burden of care.
The catalysts and objectives for this report are to:
Scope
Reasons to buy
Summary
Parkinson’s disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of Parkinson’s disease (PD) are common. In particular, PD-associated dementia and PD-associated psychosis are highly prevalent and associated with a large disease burden.
There is a pressing unmet need within Parkinson’s disease (PD), as well as PD-associated dementia and PD-associated psychosis, for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relief, there are no commercially available agents capable of preventing or slowing the course of Parkinson’s disease (PD) or its behavioral complications. This reflects the complexity of these diseases and the incomplete understanding of disease pathogenesis.
There is considerable evidence that R&D within Parkinson’s disease (PD) is thriving, despite the high risk of failure associated with product development. The Parkinson’s disease (PD) pipeline is large and diverse, comprising 456 active products. The pipeline is also highly innovative, as 51.1% of pipeline products with a disclosed molecular target are first-in-class. This is notably higher than the proportion across the industry as a whole, which is approximately 40%.
Analysis of the PD pipeline demonstrates a shift in focus from symptomatic alleviation to potential disease-modifying strategies. The pipeline comprises a range of novel mechanisms not observed in the market, including therapies that promote neurogenesis or immunomodulatory effects, and therapies that reduce neurotoxicity by preventing aggregation of misfolded proteins.
Far fewer products are in development for behavioral complications of PD. There are 16 products in development for PD-associated dementia, of which 12 have a disclosed molecular target. However, encouragingly, the majority of these products-nine in total-are first-in-class. Only six pipeline products have been identified within the PD-associated psychosis pipeline, five of which have a disclosed molecular target. However, none of these products are first-in-class.
Less than a third of products in active development for Parkinson’s disease (PD), PD-associated dementia, or PD-associated psychosis have prior involvement in licensing or co-development deals. Notably, products associated with the largest deal values are predominately first-in-class, a trend that is attributable to the stronger commercial potential of first-in-class products. Additionally, some of the largest deal values relate to gene therapies, examples of which include VYAADC-01, ‘Gene Therapy to Inhibit SNCA for Neurology,’ AXO-Lenti-PD, and OXB-101. This provides further evidence that pharma companies are diversifying their approaches by investing more substantially in more innovative molecule types.
However, of the 467 products in active development within these indications, 326 (69.8%) have no prior involvement in licensing or co-development deals and therefore represent potential investment opportunities. This includes 96 first-in-class products that act on a diverse range of targets.
The report “Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects” focuses on Parkinson’s disease (PD), as well as PD-associated dementia and PD-associated psychosis, two behavioral complications of PD associated with large quality-of-life impairments and burden of care.
The catalysts and objectives for this report are to:
- Evaluate the pipeline for PD and its associated indications and identify all first-in-class programs.
- Integrate all first-in-class molecular targets identified in the pipeline into a proprietary matrix assessment, which assesses the rationale for therapeutic intervention based on a number of factors.
- Examine the preclinical and clinical evidence for the most promising first-in-class targets in the pipeline.
- Identify key players and deals within the landscape for PD and its behavioral complications.
Scope
- The PD pipeline is large, with 456 programs in active development. Far fewer products are in development for the behavioral complications of PD. There are 16 products in development for PD-associated dementia and six products in development for PD-associated psychosis. What proportion of these products across PD and PD behavioral complications are first in class? How does first-in-class innovation vary by development stage and molecular target class?
- Innovative molecular target groups identified in the pipeline include immunomodulators, neuroprotectants, and protein misfolding and aggregation. Which molecular target classes are prominently represented in the overall and first-in-class pipelines for PD and PD behavioral complications?
- There are 351 companies active across PD and PD behavioral complications. Which companies have the most first-in-class assets in development? Which companies are highly active in terms of licensing and co-development deals for first-in-class innovation?
Reasons to buy
- Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification and staging systems, epidemiology, and marketed therapies for PD. Overviews of PD-associated dementia and PD-associated psychosis are also provided.
- Analyze the pipelines for PD, PD-associated dementia, and PD-associated psychosis, and stratify them by stage of development, molecule type, and molecular target.
- Assess the therapeutic potential of first-in-class molecular targets. Using proprietary matrix assessments, first-in-class molecular targets for PD and PD-associated dementia have been assessed and ranked according to clinical potential. A matrix assessment is not provided for PD-associated psychosis due to a lack of first-in-class innovation. Promising first-in-class targets for PD and PD-associated dementia have been reviewed in greater detail.
- Analyze company strategies in prior deals through case studies of key deals for PD first-in-class products, and recognize commercial opportunities by identifying first-in-class pipeline products that have not yet been involved in licensing or co-development deals.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Parkinson’s Disease and Behavioral Complications: Executive Summary
2.1 High Unmet Need Remains for Disease-Modifying Pharmacotherapies
2.2 Large and Innovative Parkinson’s Disease Pipeline Indicates Shift Towards Disease-Modifying Approaches
2.3 Novel Gene Therapies Attract High Levels of Investment in Parkinson’s Disease
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in Parkinson’s Disease
4.4 Epidemiology for Parkinson’s Disease
4.5 Overview for Marketed Products
4.6 Overview for Behavioral Complications in Parkinson’s Disease
4.6.1 Overview of Parkinson’s Disease-Associated Dementia
4.6.2 Overview of Parkinson’s Disease-Associated Psychosis
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between the Parkinson’s Disease Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline
6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting Alpha Synuclein for Parkinson’s Disease and Parkinson’s Disease-Associated Dementia
6.3 Pipeline Programs Targeting Microtubule-Associated Protein Tau for Parkinson’s Disease
6.4 Pipeline Programs Targeting Glial Cell Line-Derived Neurotrophic Factor for Parkinson’s Disease
6.5 Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 and Metabotropic Glutamate Receptor 5 for Parkinson’s Disease
6.6 Pipeline Programs Targeting GDNF Family Receptor Alpha 1 and GDNF Family Receptor Alpha 2 for Parkinson’s Disease
6.7 Pipeline Programs Targeting Pituitary Adenylate Cyclase-Activating Polypeptide Type I Receptor for Parkinson’s Disease
6.8 Pipeline Programs Targeting Caveolin-1 for Parkinson’s Disease-Associated Dementia
6.9 Pipeline Programs Targeting Mitogen-Activated Protein Kinase 14 for Parkinson’s Disease-Associated Dementia
7 Key Players and Deals
7.1 Overview
7.1.1 AbbVie and Voyager Therapeutics Enter into Co-development Agreement
7.1.2 Axovant Sciences Enters into Licensing Agreement with Oxford Biomedica
7.1.3 Pfizer Enters into Licensing Agreement with Arvinas
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 About the Authors
8.4.1 Analyst
8.4.2 Therapy Area Director
8.4.3 Global Director of Therapy Analysis and Epidemiology
8.4.4 Global Head and EVP of Healthcare Operations and Strategy
8.5 About the Publisher
8.6 Contact Us
8.7 Disclaimer
List of Tables
Table 1: Parkinson’s Disease and Behavioral Complications, Global, Modified Hoehn and Yahr Scale of Parkinson’s Disease Symptoms, 2017
Table 2: Parkinson’s Disease and Behavioral Complications, Global, Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), 2008
Table 3: Parkinson’s Disease and Behavioral Complications, Diagnosed Parkinson’s Disease Prevalent Cases (N) (Millions), 2016-2026
List of Figures
Figure 1: Parkinson’s Disease and Behavioral Complications, Global, Indirect and Direct Pathways in Basal Ganglia, 2019
Figure 2: Parkinson’s Disease and Behavioral Complications, Global, Parkinson’s Disease Market by Molecular Target, 2019
Figure 3: Parkinson’s Disease and Behavioral Complications, Global, Parkinson’s Disease Pipeline by Stage of Development and Molecule Type, 2019
Figure 4: Parkinson’s Disease and Behavioral Complications, Global, Pipeline for Parkinson’s Disease-Associated Dementia and Parkinson’s Disease-Associated Psychosis by Stage of Development, 2019
Figure 5: Parkinson’s Disease and Behavioral Complications, Global, Pipeline for Parkinson’s Disease-Associated Dementia by Molecule Type, 2019
Figure 6: Parkinson’s Disease and Behavioral Complications, Global, Parkinson’s Disease Pipeline by Molecular Target and Stage of Development, 2019
Figure 7: Parkinson’s Disease and Behavioral Complications, Global, Pipeline for Parkinson’s Disease-Associated Dementia and Parkinson’s Disease-Associated Psychosis by Molecular Target, 2019
Figure 8: Parkinson’s Disease and Behavioral Complications, Global, Distribution of Pipeline and Marketed Parkinson’s Disease Products by Molecular Target Class, 2019
Figure 9: Parkinson’s Disease and Behavioral Complications, Global, Distribution of Parkinson’s Disease Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 10: Parkinson’s Disease and Behavioral Complications, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Parkinson’s Disease Products by Stage of Development and Molecular Target Class, 2019
Figure 11: Parkinson’s Disease and Behavioral Complications, Global, Ratio of First-in-Class Products to First-in-Class Targets in the Parkinson’s Disease Pipeline by Stage of Development and Molecular Target Class, 2019
